Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.
Analgesics, Opioid
/ administration & dosage
Animals
Cell Degranulation
/ drug effects
Fibroblasts
/ drug effects
Guinea Pigs
Humans
Infusions, Spinal
Male
Mast Cells
/ drug effects
Models, Animal
Morphine
/ administration & dosage
Receptors, G-Protein-Coupled
/ physiology
Signal Transduction
/ physiology
Spine
/ drug effects
Journal
Anesthesiology
ISSN: 1528-1175
Titre abrégé: Anesthesiology
Pays: United States
ID NLM: 1300217
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
22
6
2019
pubmed:
22
6
2019
medline:
4
1
2020
Statut:
ppublish
Résumé
As the meningeally derived, fibroblast-rich, mass-produced by intrathecal morphine infusion is not produced by all opiates, but reduced by mast cell stabilizers, the authors hypothesized a role for meningeal mast cell/fibroblast activation. Using the guinea pig, the authors asked: (1) Are intrathecal morphine masses blocked by opiate antagonism?; (2) Do opioid agonists not producing mast cell degranulation or fibroblast activation produce masses?; and (3) Do masses covary with Mas-related G protein-coupled receptor signaling thought to mediate mast cell degranulation? In adult male guinea pigs (N = 66), lumbar intrathecal catheters connected to osmotic minipumps (14 days; 0.5 µl/h) were placed to deliver saline or equianalgesic concentrations of morphine sulfate (33 nmol/h), 2',6'-dimethyl tyrosine-(Tyr-D-Arg-Phe-Lys-NH2) (abbreviated as DMT-DALDA; 10 pmol/h; μ agonist) or PZM21 (27 nmol/h; biased μ agonist). A second pump delivered subcutaneous naltrexone (25 µg/h) in some animals. After 14 to 16 days, animals were anesthetized and perfusion-fixed. Drug effects on degranulation of human cultured mast cells, mouse embryonic fibroblast activation/migration/collagen formation, and Mas-related G protein-coupled receptor activation (PRESTO-Tango assays) were determined. Intrathecal infusion of morphine, DMT-DALDA or PZM21, but not saline, comparably increased thermal thresholds for 7 days. Spinal masses proximal to catheter tip, composed of fibroblast/collagen type I (median: interquartile range, 0 to 4 scale), were produced by morphine (2.3: 2.0 to 3.5) and morphine plus naltrexone (2.5: 1.4 to 3.1), but not vehicle (1.2: 1.1 to 1.5), DMT-DALDA (1.0: 0.6 to 1.3), or PZM21 (0.5: 0.4 to 0.8). Morphine in a naloxone-insensitive fashion, but not PZM21 or DMT-DALDA, resulted in mast cell degranulation and fibroblast proliferation/collagen formation. Morphine-induced fibroblast proliferation, as mast cell degranulation, is blocked by cromolyn. Mas-related G protein-coupled receptor activation was produced by morphine and TAN67 (∂-opioid agonist), but not by PZM21, TRV130 (mu biased ligand), or DMT-DALDA. Opiates that activate Mas-related G protein-coupled receptor will degranulate mast cells, activate fibroblasts, and result in intrathecal mass formation. Results suggest a mechanistically rational path forward to safer intrathecal opioid therapeutics.
Sections du résumé
BACKGROUND
As the meningeally derived, fibroblast-rich, mass-produced by intrathecal morphine infusion is not produced by all opiates, but reduced by mast cell stabilizers, the authors hypothesized a role for meningeal mast cell/fibroblast activation. Using the guinea pig, the authors asked: (1) Are intrathecal morphine masses blocked by opiate antagonism?; (2) Do opioid agonists not producing mast cell degranulation or fibroblast activation produce masses?; and (3) Do masses covary with Mas-related G protein-coupled receptor signaling thought to mediate mast cell degranulation?
METHODS
In adult male guinea pigs (N = 66), lumbar intrathecal catheters connected to osmotic minipumps (14 days; 0.5 µl/h) were placed to deliver saline or equianalgesic concentrations of morphine sulfate (33 nmol/h), 2',6'-dimethyl tyrosine-(Tyr-D-Arg-Phe-Lys-NH2) (abbreviated as DMT-DALDA; 10 pmol/h; μ agonist) or PZM21 (27 nmol/h; biased μ agonist). A second pump delivered subcutaneous naltrexone (25 µg/h) in some animals. After 14 to 16 days, animals were anesthetized and perfusion-fixed. Drug effects on degranulation of human cultured mast cells, mouse embryonic fibroblast activation/migration/collagen formation, and Mas-related G protein-coupled receptor activation (PRESTO-Tango assays) were determined.
RESULTS
Intrathecal infusion of morphine, DMT-DALDA or PZM21, but not saline, comparably increased thermal thresholds for 7 days. Spinal masses proximal to catheter tip, composed of fibroblast/collagen type I (median: interquartile range, 0 to 4 scale), were produced by morphine (2.3: 2.0 to 3.5) and morphine plus naltrexone (2.5: 1.4 to 3.1), but not vehicle (1.2: 1.1 to 1.5), DMT-DALDA (1.0: 0.6 to 1.3), or PZM21 (0.5: 0.4 to 0.8). Morphine in a naloxone-insensitive fashion, but not PZM21 or DMT-DALDA, resulted in mast cell degranulation and fibroblast proliferation/collagen formation. Morphine-induced fibroblast proliferation, as mast cell degranulation, is blocked by cromolyn. Mas-related G protein-coupled receptor activation was produced by morphine and TAN67 (∂-opioid agonist), but not by PZM21, TRV130 (mu biased ligand), or DMT-DALDA.
CONCLUSIONS
Opiates that activate Mas-related G protein-coupled receptor will degranulate mast cells, activate fibroblasts, and result in intrathecal mass formation. Results suggest a mechanistically rational path forward to safer intrathecal opioid therapeutics.
Identifiants
pubmed: 31225809
doi: 10.1097/ALN.0000000000002730
pii: 00000542-201907000-00027
pmc: PMC6590697
mid: NIHMS1523857
doi:
Substances chimiques
Analgesics, Opioid
0
Receptors, G-Protein-Coupled
0
Morphine
76I7G6D29C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
132-147Subventions
Organisme : NIDA NIH HHS
ID : R01 DA015353
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS102432
Pays : United States
Références
Acta Biomater. 2014 May;10(5):1856-63
pubmed: 24406200
Eur J Med Chem. 2000 Oct;35(10):895-901
pubmed: 11121615
Anesthesiology. 2003 Jul;99(1):174-87
pubmed: 12826858
Anesth Analg. 2005 Sep;101(3):728-34, table of contents
pubmed: 16115983
Br J Pharmacol. 2018 Jul;175(13):2653-2661
pubmed: 29582414
Curr Neuropharmacol. 2017;15(2):232-259
pubmed: 26861470
Neuromodulation. 2017 Feb;20(2):155-176
pubmed: 28042914
Pain Pract. 2018 Sep;18(7):889-894
pubmed: 29480977
J Pharmacol Exp Ther. 1989 Jul;250(1):1-8
pubmed: 2526212
Nucleic Acids Res. 1996 Feb 15;24(4):596-601
pubmed: 8604299
Int J Toxicol. 2018 Jan/Feb;37(1):4-27
pubmed: 29264927
Neuromodulation. 2013 Sep-Oct;16(5):459-66; discussion 466
pubmed: 23170763
Scand J Pain. 2019 Jan 28;19(1):193-206
pubmed: 30367811
Ann Surg. 1955 Dec;142(6):967-72
pubmed: 13269054
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1322-8
pubmed: 16979137
Anesthesiology. 2012 Jan;116(1):170-81
pubmed: 22139590
Anesthesiology. 2016 Aug;125(2):378-94
pubmed: 27272672
Mayo Clin Proc. 1981 Aug;56(8):516-20
pubmed: 6894954
J Invest Dermatol. 2008 May;128(5):1298-310
pubmed: 17989729
Acta Neurochir (Wien). 2006 Aug;148(8):899-901; discussion 901
pubmed: 16791432
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):185-8
pubmed: 10406986
J Psychopharmacol. 2017 Jun;31(6):730-739
pubmed: 28142305
Pain. 1981 Dec;11(3):293-346
pubmed: 6276842
Nat Struct Mol Biol. 2015 May;22(5):362-9
pubmed: 25895059
PLoS One. 2014 Jan 22;9(1):e85226
pubmed: 24465509
Toxicol Appl Pharmacol. 2018 Jan 1;338:54-64
pubmed: 29111148
Anesthesiology. 2006 Sep;105(3):581-9
pubmed: 16931993
Histochemistry. 1986;85(1):41-9
pubmed: 3733471
J Pharmacol Exp Ther. 1989 Oct;251(1):216-23
pubmed: 2795458
J Neurol. 2009 Jan;256(1):66-71
pubmed: 19221848
Mol Pain. 2017 Jan-Dec;13:1744806917740030
pubmed: 29056067
Kidney Int. 1998 Feb;53(2):350-7
pubmed: 9461094
J Histochem Cytochem. 2014 Oct;62(10):751-8
pubmed: 25023614
Anesthesiology. 2013 Mar;118(3):664-78
pubmed: 23426209
Neurosurgery. 1991 Nov;29(5):778-84
pubmed: 1961414
Curr Protoc Immunol. 2010 Aug;Chapter 7:Unit 7.37
pubmed: 20814942
Brain Res. 1986 Oct 22;385(2):300-4
pubmed: 2877713
Leuk Res. 2003 Aug;27(8):677-82
pubmed: 12801524
J Neurosci Methods. 1997 Oct 3;76(2):183-91
pubmed: 9350970
Nature. 2016 Sep 8;537(7619):185-190
pubmed: 27533032
Immunology. 1989 Mar;66(3):434-8
pubmed: 2522909
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2530-2534
pubmed: 28844982
Anesthesiology. 2006 Sep;105(3):590-8
pubmed: 16931994
Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L193-201
pubmed: 10645907
Br J Pharmacol. 1970 Jan;38(1):253-62
pubmed: 4189829
Biomaterials. 2011 Nov;32(33):8394-403
pubmed: 21864899
Eur J Pharmacol. 2016 May 5;778:158-68
pubmed: 26130122
Anesthesiology. 2003 Jul;99(1):188-98
pubmed: 12826859
Pain Med. 2002 Dec;3(4):300-12
pubmed: 15099235
J Pharmacol Exp Ther. 2003 Dec;307(3):947-54
pubmed: 14534366
Nat Chem Biol. 2017 May;13(5):529-536
pubmed: 28288109
J Immunol. 1997 Mar 1;158(5):2310-7
pubmed: 9036979